Jane Street’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$68.1M Buy
152,500
+30,700
+25% +$14.3M 0.01% 861
2025
Q4
$55.2M Sell
121,800
-23,200
-16% -$10M 0.01% 874
2025
Q3
$56.8M Buy
145,000
+50,900
+54% +$21.3M 0.01% 888
2025
Q2
$41.9M Buy
94,100
+7,000
+8% +$3.23M 0.01% 878
2025
Q1
$42.2M Sell
87,100
-58,600
-40% -$27.3M 0.01% 757
2024
Q4
$58.7M Buy
145,700
+38,300
+36% +$17.8M 0.01% 620
2024
Q3
$49.9M Buy
107,400
+50,900
+90% +$24.5M 0.01% 692
2024
Q2
$26.5M Sell
56,500
-33,300
-37% -$14.5M 0.01% 1080
2024
Q1
$37.5M Buy
89,800
+7,700
+9% +$3.26M 0.01% 783
2023
Q4
$33.4M Sell
82,100
-36,900
-31% -$13.6M 0.01% 902
2023
Q3
$41.4M Buy
119,000
+49,800
+72% +$17.4M 0.01% 641
2023
Q2
$24.4M Sell
69,200
-23,400
-25% -$7.88M 0.01% 1035
2023
Q1
$29.2M Buy
92,600
+9,200
+11% +$2.76M 0.01% 773
2022
Q4
$24.1M Sell
83,400
-6,400
-7% -$1.95M 0.01% 877
2022
Q3
$26M Sell
89,800
-72,800
-45% -$20.9M 0.01% 876
2022
Q2
$45.8M Sell
162,600
-41,400
-20% -$11.1M 0.02% 588
2022
Q1
$53.2M Sell
204,000
-23,800
-10% -$5.65M 0.02% 659
2021
Q4
$50M Buy
227,800
+53,200
+30% +$10.3M 0.02% 660
2021
Q3
$31.7M Sell
174,600
-3,900
-2% -$761K 0.01% 818
2021
Q2
$36M Hold
178,500
0.01% 711
2021
Q1
$38.4M Buy
178,500
+112,600
+171% +$24.7M 0.02% 585
2020
Q4
$15.6M Buy
65,900
+15,300
+30% +$3.51M 0.01% 1055
2020
Q3
$13.8M Sell
50,600
-144,700
-74% -$39.9M 0.01% 986
2020
Q2
$56.7M Buy
195,300
+131,100
+204% +$35.5M 0.04% 318
2020
Q1
$15.3M Buy
64,200
+35,100
+121% +$8.05M 0.01% 557
2019
Q4
$6.37M Sell
29,100
-34,100
-54% -$6.9M 0.01% 901
2019
Q3
$10.7M Buy
63,200
+42,300
+202% +$7.48M 0.02% 563
2019
Q2
$3.83M Sell
20,900
-7,600
-27% -$1.33M 0.01% 1269
2019
Q1
$5.24M Buy
28,500
+11,400
+67% +$2.11M 0.01% 1116
2018
Q4
$2.83M Sell
17,100
-12,400
-42% -$2.15M 0.01% 1376
2018
Q3
$5.69M Sell
29,500
-13,500
-31% -$2.4M 0.01% 948
2018
Q2
$7.31M Buy
43,000
+21,700
+102% +$3.36M 0.02% 783
2018
Q1
$3.47M Buy
21,300
+13,700
+180% +$2.24M 0.01% 1268
2017
Q4
$1.14M Sell
7,600
-36,300
-83% -$5.37M ﹤0.01% 2195
2017
Q3
$6.67M Buy
43,900
+14,900
+51% +$2.24M 0.02% 696
2017
Q2
$3.74M Sell
29,000
-7,400
-20% -$891K 0.01% 965
2017
Q1
$3.98M Buy
36,400
+27,300
+300% +$2.4M 0.02% 845
2016
Q4
$670K Sell
9,100
-19,600
-68% -$1.59M ﹤0.01% 2525
2016
Q3
$2.5M Buy
28,700
+23,600
+463% +$2.23M 0.01% 1019
2016
Q2
$439K Buy
5,100
+1,100
+28% +$95K ﹤0.01% 2900
2016
Q1
$318K Buy
4,000
+2,200
+122% +$199K ﹤0.01% 3134
2015
Q4
$226K Buy
+1,800
New +$217K ﹤0.01% 3437
2015
Q3
Sell
-6,100
Closed -$753K 4208
2015
Q2
$753K Buy
+6,100
New +$769K ﹤0.01% 1857

Other funds holding VRTX

Jane Street's VRTX Position: Q1 2026 in Review

Jane Street increased its Vertex Pharmaceuticals (VRTX) stake by 993% in Q1 2026, buying an estimated $52.1M and bringing the position to 122,946 shares worth $54.9M. The position accounts for 0.01% of the portfolio, ranked #990.

Jane Street first reported a position in VRTX in Q2 2013 and has held it in 49 quarters since. The position peaked at $142M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Jane Street held 122,946 shares of Vertex Pharmaceuticals worth $54.9M as of Q1 2026.
  • Jane Street bought 111,700 Vertex Pharmaceuticals shares in Q1 2026, an estimated $52.1M.
  • Vertex Pharmaceuticals made up 0.01% of Jane Street's portfolio in Q1 2026, its #990 holding.
  • Jane Street first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • Jane Street's Vertex Pharmaceuticals position peaked at $142M in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.